Who is sponsoring NCT01352416?

NCT01352416 is sponsored by Corewell Health East.

What drugs are being tested in NCT01352416?

Interventions in NCT01352416: Ranolazine, Placebo.

What condition does NCT01352416 study?

NCT01352416 studies Heart; Dysfunction Postoperative, Cardiac Surgery.

Is NCT01352416 still recruiting?

NCT01352416 is currently terminated. Last updated 8 November 2016.

Are results published for NCT01352416?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2016-11-08 · How we verify

NCT01352416

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

Terminated Phase 3 Results posted Last updated 8 November 2016

What this trial tests

Phase 3 trial testing Ranolazine in Heart; Dysfunction Postoperative, Cardiac Surgery in 15 participants. Terminated before completion.

Timeline

1 September 2010

Primary endpoint
1 November 2012

1 November 2012

Quick facts

Lead sponsor	Corewell Health East
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	15
Start date	1 September 2010
Primary completion	1 November 2012
Estimated completion	1 November 2012
Sites	2 locations across United States

Drugs / interventions tested

Ranolazine (RANOLAZINE) — full drug profile →
Placebo

Conditions studied

Heart; Dysfunction Postoperative, Cardiac Surgery — all drugs for Heart; Dysfunction Postoperative, Cardiac Surgery →

Sponsor

Corewell Health East — full company profile →

Who can join

22 and older, any sex, with Heart; Dysfunction Postoperative, Cardiac Surgery. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Freedom From Any Episode of Post Operative Atrial Fibrillation Longer Than 6 Hours Duration Occurring During the Study Period.
Time frame: The time between the completion of the operation and hospital discharge or 14 days post operative if the hospitalzation is prolonged
Freedom from any episode of post operative Atrial Fibrillation (AF) longer than 6 hours duration occurring during the study period. To document post operative atrial fibrillation.

Sponsor's own description

The objective of this study is to show that ranolazine is a safe, viable and potent alternative for post-operative atrial fibrillation suppression in patients undergoing cardiac surgery

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tic-Tac: A Translational Approach in Mechanisms Associated with Irregular Heartbeat and Sinus Rhythm Restoration in Atrial Fibrillation Patients.
Parra-Lucares A, Villa E, Romero-Hernández E, Méndez-Valdés G, et al · · 2023 · PMID 37629037 · DOI 10.3390/ijms241612859

Verify or expand the search:

Other trials of Ranolazine

Trials testing the same drug.

NCT04456517 — Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy · Phase 2 · terminated
NCT03401502 — A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency · NA · completed
NCT03486561 — Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine) · Phase 4 · unknown
NCT03257683 — RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain · withdrawn
NCT03070470 — CiPA Phase 1 ECG Biomarker Validation Study · Phase 1 · completed

Other Corewell Health East trials

Trials by the same sponsor.

NCT06150599 — Sacral Neuromodulation for Chronic Pelvic Pain · NA · recruiting
NCT06154980 — Randomized Controlled Comparison of Pre-op TLIP vs Intra-op TLIP · NA · withdrawn
NCT06074237 — Improving Vaccine Counseling Skills Among Residents Using Educational Modules and Standardized Patient Encounters · NA · completed
NCT05297305 — Onlay Versus Inlay Humeral Component in Reverse Total Shoulder Arthroplasty · NA · terminated
NCT04074044 — Evaluation of a New Bladder Health Mobile Application in Pregnancy · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01352416 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Corewell Health East
Last refreshed: 8 November 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01352416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing